North Brunswick, NJ – According to filings with the U.S. Securities and Exchange Commission, BioAegis Therapeutics is raising $7,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Susan Levinson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About BioAegis Therapeutics

We are a clinical stage private company focused on developing therapies for infectious, inflammatory and degenerative diseases. Our programs capitalize on Evolutionary Wisdom with a natural protein, plasma gelsolin, which has fulfilled this role for vertebrates for millennia. Plasma Gelsolin (pGSN) is a master regulator of the immune system. It is a unique anti-inflammatory without immunosuppressive properties. In a wide range of diseases, it balances the inflammatory process to prevent the spread of excess inflammation while simultaneously enhancing antimicrobial defense; thus preventing severe consequences, and greatly improving survival.

To learn more about BioAegis Therapeutics, visit http://bioaegistherapeutics.com/

Contact:
Susan Levinson, Chief Executive Officer
973-539-4552
slevinson@bioaegistherapeutics.com
https://www.linkedin.com/in/susanlevinson/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved